My­lan boosts EpiPen pro­grams amid crit­i­cism

Baltimore Sun - - NATION & WORLD - — As­so­ci­ated Press

My­lan is bulk­ing up pro­grams that help pa­tients pay for its EpiPen emer­gency al­lergy treat­ment af­ter weath­er­ing heated crit­i­cism about an av­er­age cost that has soared over the past decade. But the drug­maker didn’t budge on its price hikes Thurs­day, which have drawn ire both in Congress and from fam­i­lies that must shell out in­creas­ingly large sums for the po­ten­tially life-sav­ing treat­ment. That means the in­sur­ers and em­ploy­ers that pay the bulk of the EpiPen cost for many pa­tients will con­tinue to do so, con­tribut­ing to higher health in­surance costs. The av­er­age price of a two-dose EpiPen pack­age climbed to about $608 ear­lier this year, up more than 500 per­cent from around $94 nine years ago, ac­cord­ing to the El­se­vier Clin­i­cal So­lu­tions’ Gold Stan­dard Drug Data­base.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.